Cicor Technologies Ltd
/ Key word(s): Partnership
Bronschhofen, October 12, 2023 – The Cicor Group (SIX Swiss Exchange: CICN) announces today that it has signed a Memorandum of Understanding with Clayens Group for a strategic collaboration to create global one-stop CDMO solutions for demanding applications in medical and industrial markets with a focus on smart drug delivery devices. Cicor is one of Europe's fastest growing manufacturers of high-reliability electronics for medical, industrial and aerospace & defence applications headquartered in Boudry, Switzerland. Clayens is a European leader in the processing of polymers, composites and precision metal parts, headquartered in Genas, France. With complementary global manufacturing capabilities, a shared vision for innovation and excellence, and extensive technology and market expertise in their respective fields, Cicor and Clayens bring together 7,500 employees at 46 production sites in 16 countries across Europe, East Asia and North America, including 20 state-of-the-art cleanrooms. This strategic partnership enables both companies to offer a one-stop shop for customized, integrated technology solutions that are unmatched in innovation, quality and efficiency, from concept to market, regardless of complexity. Customers, particularly in the medical technology and industrial markets, will benefit from the combination of Cicor's and Clayens' complementary skills and technologies. The joint offering specifically responds to the growing demand for smart drug delivery devices that significantly improve patient care, enable traceability of high value medicine and ultimately reduce healthcare cost. While developing a joint offering entirely focused on new programs, both companies will remain independent of each other and work at arms-length. The collaboration of Cicor and Clayens as independent groups is endorsed by One Equity Partners (OEP), a shareholder in both companies. Cicor is committed to leveraging this strategic collaboration to drive innovation and create value for all stakeholders, reinforcing its commitment to excellence in the EMS and plastics industries. Contact:
The Cicor Group is a globally active provider of full-cycle electronic solutions from research and development to manufacturing and supply chain management. Cicor’s approximately 2,500 employees at 15 locations are serving leaders from the medical, industrial and aerospace & defence industries. Cicor creates value to its customers through the combination of customer-specific development solutions, high-tech components, as well as electronic device manufacturing. The shares of Cicor Technologies Ltd. are traded at the SIX Swiss Exchange (CICN). For further information, please visit the website www.cicor.com.
End of Media Release |
Language: | English |
Company: | Cicor Technologies Ltd |
c/o Cicor Management AG, Gebenloostraße 15 | |
9552 Bronschhofen | |
Switzerland | |
Phone: | +41719137300 |
Fax: | +41719137301 |
E-mail: | info@cicor.com |
Internet: | www.cicor.com |
ISIN: | CH0008702190 |
Valor: | 870219 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1746803 |
End of News | EQS News Service |
|
1746803 12.10.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.